Healthcare Technology Featured Article

December 18, 2013

MultiCorp Acquires Majority Ownership of Patented Migraine Medication


MultiCorp International, Inc., announced Tuesday that is has acquired a 70 percent ownership in a patented medication shown to relieve migraine headaches. The company plans to start clinical trials during the first quarter of 2014 and will work with the physician that developed the medication to get FDA approval. More than 37 million people in the U.S. and 330 million people worldwide currently suffer from migraines on a constant basis, according to Migraine.com.

“With the average cost of $145 per month in medication for migraine sufferers, the market for this product is exponential here in the U.S. and globally," the company stated in its announcement.

Companies interested in assisting MultiCorp with the clinical trials are being asked to send an email to [email protected].

MultiCorp, which is also known for operating in the entertainment, hospitality, property development, oil & gas, and construction industries, has worked in the past with healthcare companies such as United Healthcare, Kaiser and Tenet, according to its Web site.

In other migraine treatment-related news, the FDA has approved the use of the Cerena Transcranial Magnetic Stimulator to treat migraine sufferers, according to the Atlanta Journal-Constitution. The device works by stimulating the occipital cortex in the brain via magnetic energy. It specifically helps relieve the pain that is preceded by aura, the type of migraine that causes warning signs such as dizziness and eyesight trouble.

The healthcare industry is also continuing to learn more about what triggers migraine headaches and what can be done to treat them. A recent study showed that people that suffer from both migraine headaches and rhinitis get more headaches than those that don’t suffer from rhinitis, according to The Huffington Post.

Out of the 6,000 that participated in the study, two-thirds suffered from both migraines and rhinitis and those that had rhinitis had a 33 percent greater headache frequency than those that only suffered from migraines. According to study researcher Richard Lipton, M.D., of Montefiore Medical Center and the Albert Einstein College of Medicine, these findings might change the way that doctors treat migraine sufferers in the future.

"If rhinitis exacerbates migraine, as these results suggest, treating rhinitis may provide an important approach to relieving headache in people with both disorders,” Lipton said in a statement.




Edited by Cassandra Tucker
Get stories like this delivered straight to your inbox. [Free eNews Subscription]




SHARE THIS ARTICLE



FREE eNewsletter

Click here to receive your targeted Healthcare Technology Community eNewsletter.
[Subscribe Now]